These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21614637)

  • 1. Epithelial profiling of antibiotic controlled release respiratory formulations.
    Ong HX; Traini D; Bebawy M; Young PM
    Pharm Res; 2011 Sep; 28(9):2327-38. PubMed ID: 21614637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia.
    Ong HX; Traini D; Cipolla D; Gonda I; Bebawy M; Agus H; Young PM
    Pharm Res; 2012 Dec; 29(12):3335-46. PubMed ID: 22833052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of inhalable liposomal powder formulations and evaluation of their in vitro drug delivery behavior in Calu-3 human lung epithelial cells.
    Yu S; Yuan H; Chai G; Peng K; Zou P; Li X; Li J; Zhou F; Chan HK; Zhou QT
    Int J Pharm; 2020 Aug; 586():119570. PubMed ID: 32593649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation.
    Ong HX; Benaouda F; Traini D; Cipolla D; Gonda I; Bebawy M; Forbes B; Young PM
    Eur J Pharm Biopharm; 2014 Jan; 86(1):83-9. PubMed ID: 23851077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
    Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
    Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection.
    Arora S; Haghi M; Loo CY; Traini D; Young PM; Jain S
    Mol Pharm; 2015 Jun; 12(6):2001-9. PubMed ID: 25923171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled release antibiotics for dry powder lung delivery.
    Adi H; Young PM; Chan HK; Salama R; Traini D
    Drug Dev Ind Pharm; 2010 Jan; 36(1):119-26. PubMed ID: 19656005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cospray dried antibiotics for dry powder lung delivery.
    Adi H; Young PM; Chan HK; Stewart P; Agus H; Traini D
    J Pharm Sci; 2008 Aug; 97(8):3356-66. PubMed ID: 17990305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach.
    Karimi K; Pallagi E; Szabó-Révész P; Csóka I; Ambrus R
    Drug Des Devel Ther; 2016; 10():3331-3343. PubMed ID: 27784991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model Calculations of Regional Deposition and Disposition for Single Doses of Inhaled Liposomal and Dry Powder Ciprofloxacin.
    Martin AR; Finlay WH
    J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):49-60. PubMed ID: 28708440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
    Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
    Adi H; Young PM; Chan HK; Agus H; Traini D
    Eur J Pharm Sci; 2010 Jun; 40(3):239-47. PubMed ID: 20371286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of ciprofloxacin nanocrystals within liposomes by spray drying for controlled release via inhalation.
    Khatib I; Tang P; Ruan J; Cipolla D; Dayton F; Blanchard JD; Chan HK
    Int J Pharm; 2020 Mar; 578():119045. PubMed ID: 31981702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aerosol Performance and Stability of Liposomes Containing Ciprofloxacin Nanocrystals.
    Cipolla D; Wu H; Gonda I; Chan HK
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):411-22. PubMed ID: 26469306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
    Karimi K; Katona G; Csóka I; Ambrus R
    J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of mannitol on the transport of ciprofloxacin across respiratory epithelia.
    Ong HX; Traini D; Salama R; Anderson SD; Daviskas E; Young PM
    Mol Pharm; 2013 Aug; 10(8):2915-24. PubMed ID: 23803159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols.
    Salama RO; Traini D; Chan HK; Young PM
    Eur J Pharm Biopharm; 2008 Sep; 70(1):145-52. PubMed ID: 18534832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.
    Aquino RP; Prota L; Auriemma G; Santoro A; Mencherini T; Colombo G; Russo P
    Int J Pharm; 2012 Apr; 426(1-2):100-107. PubMed ID: 22301426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
    Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
    Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
    Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Li J; Chan HK
    Eur J Pharm Biopharm; 2019 Sep; 142():543-552. PubMed ID: 31398437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.